An oral vaccine against candidiasis generated by a yeast molecular display system

Adachi, 2010, Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7, Vaccine, 28, 2810, 10.1016/j.vaccine.2010.02.005

Aoki, 2011, Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in Candida albicans, J Biochem, 150, 431, 10.1093/jb/mvr073

Aoki, 2013, Time-course proteomic profile of Candida albicans during adaptation to a fetal serum, Pathog Dis, 67, 67, 10.1111/2049-632X.12003

Benko, 1999, Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro, J Antimicrob Chemother, 43, 675, 10.1093/jac/43.5.675

Berner, 2008, Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations, Appl Microbiol Biotechnol, 80, 1053, 10.1007/s00253-008-1618-8

Enache-Angoulvant, 2005, Invasive Saccharomyces infection: a comprehensive review, Clin Infect Dis, 41, 1559, 10.1086/497832

Hanahan, 1983, Studies on transformation of Escherichia coli with plasmids, J Mol Biol, 166, 557, 10.1016/S0022-2836(83)80284-8

Hube, 1997, Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence, Infect Immun, 65, 3529, 10.1128/IAI.65.9.3529-3538.1997

Ito, 1983, Transformation of intact yeast cells treated with alkali cations, J Bacteriol, 153, 163, 10.1128/JB.153.1.163-168.1983

Kuroda, 2009, Enhancement of display efficiency in yeast display system by vector engineering and gene disruption, Appl Microbiol Biotechnol, 82, 713, 10.1007/s00253-008-1808-4

Li, 2011, Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice, Vaccine, 29, 5526, 10.1016/j.vaccine.2011.05.030

Montagnoli, 2004, Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis, Med Mycol, 42, 319, 10.1080/13693780310001644653

Morschhäuser, 2002, The genetic basis of fluconazole resistance development in Candida albicans, Biochim Biophys Acta, 1587, 240, 10.1016/S0925-4439(02)00087-X

Noble, 2007, Genetics of Candida albicans, a diploid human fungal pathogen, Annu Rev Genet, 41, 193, 10.1146/annurev.genet.41.042007.170146

Nucci, 2005, Emerging fungal diseases, Clin Infect Dis, 41, 521, 10.1086/432060

Pfaller, 2007, Epidemiology of invasive candidiasis: a persistent public health problem, Clin Microbiol Rev, 20, 133, 10.1128/CMR.00029-06

Rodloff, 2011, Epidemiology and antifungal resistance in invasive candidiasis, Eur J Med Res, 16, 187, 10.1186/2047-783X-16-4-187

Rodríguez, 2009, β-Glucan administration enhances disease resistance and some innate immune responses in zebrafish (Danio rerio), Fish Shellfish Immunol, 27, 369, 10.1016/j.fsi.2009.02.007

Shibasaki, 2007, Construction of a novel synergistic system for production and recovery of secreted recombinant proteins by the cell surface engineering, Appl Microbiol Biotechnol, 75, 821, 10.1007/s00253-007-0868-1

Shibasaki, 2009, Molecular display technology using yeast - arming technology, Anal Sci, 25, 41, 10.2116/analsci.25.41

Tamaru, 2006, Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine, Biotechnol Prog, 22, 949, 10.1021/bp060130x

Xin, 2011, Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis, Clin Vaccine Immunol, 18, 1656, 10.1128/CVI.05215-11